May 20, 2024 12:11 am
Schillaci and Roccella developing new guidelines for triptorelin in managing dysphoria

The Ministry of Health and the Ministry of Family have come together to discuss the issue of gender dysphoria in minors, with a particular focus on the use of triptorelin, a puberty-blocking drug. Ministers Orazio Schillaci and Eugenia Roccella are leading this effort, bringing together a team of technicians and experts to develop new guidelines based on scientific literature and experiences from other countries.

The two ministries have already conducted extensive research and work on this issue, involving scientific societies, the National Bioethics Committee, and a survey conducted in various regions regarding the clinical and financial aspects of prescribing triptorelin. Their joint statement announced this initiative and highlighted the progress that has been made so far.

Moving forward, the ministries have requested a report from AIFA on the therapeutic indications for triptorelin in cases of gender dysphoria in minors. This collaborative effort aims to provide clear guidelines for the use of this drug in future cases, ensuring that it is used safely and effectively for those who need it most. The composition of the expert panel will be finalized in the coming days to further advance this important discussion.

Leave a Reply